Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Radical -xh acid – or anhydride – acid halide or salt thereof...
Reexamination Certificate
2005-11-11
2011-11-22
Kosack, Joseph (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Radical -xh acid, or anhydride, acid halide or salt thereof...
C514S551000, C560S169000, C562S560000
Reexamination Certificate
active
08063104
ABSTRACT:
Compounds of formula (I) have been found to be useful as inhibitors of DDAH. The present invention thus provides the use of a compound of formula (I), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in the treatment of a disease whose pathology is affected by DDAH
REFERENCES:
patent: 4530920 (1985-07-01), Nestor et al.
patent: 4659693 (1987-04-01), Nestor
patent: 4686283 (1987-08-01), Nestor, Jr. et al.
patent: 4789681 (1988-12-01), Sportoletti et al.
patent: 5318992 (1994-06-01), Whitten et al.
patent: 5352796 (1994-10-01), Hoeger et al.
patent: 5554638 (1996-09-01), Dewhirst et al.
patent: 5859295 (1999-01-01), Crooks et al.
patent: 5972940 (1999-10-01), Broquet et al.
patent: 6716436 (2004-04-01), Seguin
patent: 2002/0156129 (2002-10-01), Kuraishi et al.
patent: 0097031 (1983-12-01), None
patent: 0472220 (1992-02-01), None
patent: 1022268 (2000-07-01), None
patent: 1038864 (2000-09-01), None
patent: WO-99/31052 (1999-06-01), None
patent: WO-0004058 (2000-01-01), None
patent: WO-00/40548 (2000-07-01), None
patent: WO-00/51623 (2000-09-01), None
patent: WO-03097085 (2003-11-01), None
patent: WO-2006/051314 (2006-05-01), None
Atkinson et al. Bioorg. Med. Chem. Lett. 1999, 9, 2953-2958.
Rossiter et al. J. Med. Chem. 2005, 48, 4670-4678.
Jordan, V. C. Nature Reviews: Drug Discovery, 2, 2003, pp. 205-213.
Luo et al. (Cell, 2009, 136, pp. 823-837).
Atkinson et al., “Guanidine-Substituted Imidazoles as Inhibitors of Nitric Oxide Synthase”; Bioorganic and Medicinal Chemistry Letters; Oct. 18, 1999; 2953-2958; vol. 9(20).
Database CA [Online] Chemical Abstract Service, Columbus, Ohio, US, Phuket et al., Synthesis and structure-activity studies of some antitumor congeners of L-canavanine XP002374544; Database accession No. 1997:628412; abstract; Drug Development Research; vol. 40(4); 1997 325-332.
Database CA [Online] Chemical Abstract Service, Columbus, Ohio, Kennedy et al; “A facile route to cyclic and acyclic alkylarginines”; XP002374545; Database accession No. 1998:138426; abstract; Synthetic Communications; vol. 28 (4); 1998; 741-746.
Database Caplus [Online] Chemical Abstract Services, Columbus, Ohio, US; Hevelke et al., “Synthesis of arginine peptides with N7, N8-(1, 2-dihydroxycyclohex-1, 2-ylene) protection. Reaction of 1, 2-cyclohexanedione with arginine and lysine”; XP002374543; Database accession No. 1982:616659; Monatshefte Fuer Chemie; vol. 113 (4); 1982; 457-473.
Kennedy et al., “Design rationale, synthesis, and characterization of non-natural analogs of the cationic amino acids arginine and lysine”; J Pept Res.; Apr. 2000; 348-58; vol. 55(4).
Nestor et al., “Potent, long-acting luteinizing hormone-releasing hormone antagonists containing new synthetic amino acids: N,N′-dialkyl-D-homoarginines”, J Med Chem. Jan. 1988; 65-72; vol. 31(1).
Olken et al., “NG-allyl- and NG-cyclopropyl-L-arginine: two novel inhibitors of macrophage nitric oxide synthase”; J-Med-Chem; Mar. 20, 1992; 1137-44; vol. 35(6).
Patthy et al., “Reversible modification of arginine residues. Application to sequence studies by restriction of tryptic hydrolysis to lysine residues”; J Biol Chem.; Jan. 25, 1975; 557-564; vol. 250(2).
Robertson et al., “Inhibition of Bovine Brain Nitric Oxide synthase”; Bioorganic Chemistry; 1995; 144-151; vol. 23.
Rossiter et al., “Selective substrate-based inhibitors of mammalian dimethylarginine dimethylaminohydrolase”; J Med Chem.; Jul. 14, 2005; 4670-8; vol. 48(14).
Shlomo et al., “Synthesis of Guandino-N-Alkylarginines by the use of Polymeric Psedoureas”; J. Org. Cem.; 1981; 808-809; XP002374531; vol. 46.
Wagenaar et al., “Methodology for the Preparation of N-Guanidino-Modified Arginines and Related Derivatives”, J. Org. Chem.; 1993; 4331-4338; vol. 58 (1).
Zhang et al., “Potent and selective inhibition of neuronal nitric oxide synthase by N omega-propyl-L-arginine”, J-Med-Chem.; Nov. 21, 1997; 3869-70; 40(24): vol. 40(24).
Bredt et al., “Nitric oxide mediates glutamate-linked enhancement of cGMP levels in the cerebellum”, Proc Natl Acad Sci U S A., Nov. 1989; 9030-9033, vol. 86(22).
Dawson et al, “A microtiter-plate assay of human NOS Isoforms”, Methods in Molecular Biology, 1998, 237-242, vol. 100.
Feichtinger et al., “Triurethane-Protected Guanidines and Triflyldiurethane-Protected Guanidines: New Reagents for Guanidinylation Reactions”, J. Org. Chem., 1998, 8432 -8439, vol. 63 (23).
Hullan et al., “The hydrazine derivative aminoguanidine inhibits the reaction of tetrahydrofolic acid with hydroxymethylarginine biomolecule”, Acta-Biol-Hung., 1998; 265-73, vol. 49(2-4).
Kostourou et al., “Dimethylarginine dimethylaminohydrolase I enhances tumour growth and angiogenesis”, British Journal of Cancer, 2002, 673-680, vol. 87.
Kostourou et al., “Effects of overexpression of dimethylarginine dimethylaminohydrolase on tumour angiogenesis assessed by susceptibility Magnetic resonance imaging”, Cancer Res., 2003, 4960-4699, vol. 63.
Leiper et al., “Biological significance of endogenous methylarginines that inhibit nitric oxide synthases”, Cardiovasc Res., Aug. 15, 1999; 542-8, vol. 43(3).
Macallister et al., “Regulation of nitric oxide synthesis by dimethylarginine dimethylaminohydrolase”, Br J Pharmacol., Dec. 1996; 1533-1540, vol. 119(8).
Ogawa et al., “Purification and properties of a new enzyme, NG,NG-dimethylarginine dimethylaminohydrolase, from rat kidney”, J. Biol. Chem., Jun. 1989, 10205-10209, vol. 264(17).
Okuno et al., “Accumulated endogenous nitric oxide synthase inhibitors in inhibiting urethral relaxation following estrogen supplementation in ovariectomized rabbits”, The Journal of Urology, Jul. 2004, 360-364, vol. 172(1).
Robinson et al., “Animal models for target and/or drug evaluation”, “Overexpression of dimethylarginine dimethylaminohydrolase (ddah) enhances tumor growth, angiogenesis and hypoxia”, Clinical Cancer Research, Dec. 2003, vol. 9(Poster Session C, No. C26).
Smith et al., “Dimethylarginine dimethylaminohydrolase activity modulates ADMA levels, VEGF expression, and cell phenotype”, Biochemical and Biophysical Research Communications, 2003, 984-989, vol. 308 (4).
Thuring et al., “Comparative study of the active site caging of serine proteases: thrombin and factor Xa”, Biochemistry, Feb. 12, 2002; 2002-13, vol. 41(6).
Leiper, James et al.; “Disruption of methylarginine metabolism impairs vascular homeostasis”; NATURE MEDICINE; Feb. 2007; vol. 13, No. 2; pp. 198-203.
Applicant's Table Showing Additional Results.
Hartzoulakis Basil
Leiper James Mitchell
Rossiter Sharon
Selwood David Lawrence
Vallance Patrick John Thompson
Coughlin Matthew
Fulbright & Jaworski L.L.P.
Kosack Joseph
UCL Business PLC
LandOfFree
Guanidine derivatives as inhibitors of DDAH does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Guanidine derivatives as inhibitors of DDAH, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Guanidine derivatives as inhibitors of DDAH will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4281511